MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

K201 is a topical and steroid-free treatment of mild to moderate atopic eczema which is designed to alleviate itching and reduce dryness as well as prevent bacterial- and fungal infections, without risk for development of resistance. The phase II clinical study was a comparative study where patients were treated twice daily during 4 weeks with either K201 or a moisturising pharmaceutical. The patients were evaluated both clinically and by a set of objective variables. Atopic eczema affects approximately 15-20 percent of all children and 2-3 percent of the adult population

"We are pleased with the results of the phase II study, which indicates that K201 can provide significant benefits in the treatment of atopic eczema", says Moberg Derma's CEO, Peter Wolpert.

Moberg Derma is developing a portfolio of medical products for skin disorders based on the company’s patented technology as well as acquired projects. This spring the company announced its first commercial agreement and it intends to expand its existing product portfolio through in-house development as well as through further acquisitions.